PYRAZINAMIDE

First approved in 1955

Details

Stereochemistry	ACHIRAL
Molecular Formula	C5H5N3O
Molecular Weight	123.1127
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C1=CN=CC=N1

InChI

InChIKey=IPEHBUMCGVEMRF-UHFFFAOYSA-N

InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257bd8cf-74d7-45db-bf25-354a8d26634e
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00339 https://en.wikipedia.org/wiki/Pyrazinamide

Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. Pyrazinamide diffuses into M. tuberculosis, where the enzyme pyrazinamidase converts pyrazinamide to the active form pyrazinoic acid. Under acidic conditions, the pyrazinoic acid that slowly leaks out converts to the protonated conjugate acid, which is thought to diffuse easily back into the bacilli and accumulate. The net effect is that more pyrazinoic acid accumulates inside the bacillus at acid pH than at neutral pH. Pyrazinoic acid was thought to inhibit the enzyme fatty acid synthase (FAS) I, which is required by the bacterium to synthesise fatty acids. However, this theory was thought to have been discounted. However, further studies reproduced the results of FAS I inhibition as the putative mechanism first in whole cell assay of replicating M. tuberculosis bacilli which have shown that pyrazinoic acid and its ester inhibit the synthesis of fatty acids . This study was followed by in vitro assay of tuberculous FAS I enzyme that tested the activity with pyrazinamide, pyrazinoic acid and several classes of pyrazinamide analogs. Pyrazinamide and its analogs inhibited the activity of purified FAS I. It has also been suggested that the accumulation of pyrazinoic acid disrupts membrane potential and interferes with energy production, necessary for survival of M. tuberculosis at an acidic site of infection. Pyrazinoic acid has also been shown to bind to the ribosomal protein S1 (RpsA) and inhibit trans-translation. This may explain the ability of the drug to kill dormant mycobacteria

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Fatty acid synthase 5 Target ID: CHEMBL2011 Sources: http://www.drugbank.ca/drugs/DB00339	Inhibitor 8297
70S ribosome 16 Target ID: CHEMBL2363965 Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=21835980	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Tuberculosis 83 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257bd8cf-74d7-45db-bf25-354a8d26634e	Curative		Approved 8429	PYRAZINAMIDE Approved Use Pyrazinamide Launch Date 3.7065601E10

C_max

Value	Dose	Co-administered	Analyte	Population
38.2 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23629715	27.8 mg/kg bw 3 times / day steady-state, oral dose: 27.8 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered: Isoniazid \| Rifampicin \| Ethambutol	Isoniazid \| Rifampicin \| Ethambutol	PYRAZINAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
38.7 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2737233	27 mg/kg bw single, oral dose: 27 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		PYRAZINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
344 mg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23629715	27.8 mg/kg bw 3 times / day steady-state, oral dose: 27.8 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered: Isoniazid \| Rifampicin \| Ethambutol	Isoniazid \| Rifampicin \| Ethambutol	PYRAZINAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
520 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2737233	27 mg/kg bw single, oral dose: 27 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		PYRAZINAMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23629715	27.8 mg/kg bw 3 times / day steady-state, oral dose: 27.8 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered: Isoniazid \| Rifampicin \| Ethambutol	Isoniazid \| Rifampicin \| Ethambutol	PYRAZINAMIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1500 mg 1 times / day multiple, oral Recommended Dose: 1500 mg, 1 times / day Route: oral Route: multiple Dose: 1500 mg, 1 times / day Co-administed with:: ofloxacin, p.o(800 mg/day; 6 months) Sources: https://pubmed.ncbi.nlm.nih.gov/8139647	healthy n = 16 Health Status: healthy Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8139647	Disc. AE: Arthralgia, Distress gastrointestinal... AEs leading to discontinuation/dose reduction: Arthralgia (43.75%) Distress gastrointestinal (37.5%) Pruritus (25%) Fatigue (25%) Generalized maculopapular rash (18.8%) Insomnia (18.8%) Vertigo (12.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/8139647
20 mg/kg 1 times / day multiple, oral Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg, 1 times / day Co-administed with:: rifampin, p.o(600 mg/d; 2 months) Sources: https://pubmed.ncbi.nlm.nih.gov/12379063 Page: p.643	unhealthy n = 207 Health Status: unhealthy Condition: Tuberculosis Sex: M+F Population Size: 207 Sources: https://pubmed.ncbi.nlm.nih.gov/12379063 Page: p.643	Disc. AE: Hepatotoxicity... AEs leading to discontinuation/dose reduction: Hepatotoxicity (5.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/12379063 Page: p.643
30 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 30 mg/kg, 1 times / day Route: oral Route: multiple Dose: 30 mg/kg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=257bd8cf-74d7-45db-bf25-354a8d26634e&type=display#LINK_5b1b9b20-2ad0-4c1c-b6cb-e086db370aff	unhealthy Health Status: unhealthy Condition: Tuberculosis Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=257bd8cf-74d7-45db-bf25-354a8d26634e&type=display#LINK_5b1b9b20-2ad0-4c1c-b6cb-e086db370aff	Disc. AE: Hepatotoxicity... AEs leading to discontinuation/dose reduction: Hepatotoxicity Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=257bd8cf-74d7-45db-bf25-354a8d26634e&type=display#LINK_5b1b9b20-2ad0-4c1c-b6cb-e086db370aff

AEs

AE	Significance	Dose	Population
Vertigo	12.5% Disc. AE	1500 mg 1 times / day multiple, oral Recommended Dose: 1500 mg, 1 times / day Route: oral Route: multiple Dose: 1500 mg, 1 times / day Co-administed with:: ofloxacin, p.o(800 mg/day; 6 months) Sources: https://pubmed.ncbi.nlm.nih.gov/8139647	healthy n = 16 Health Status: healthy Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8139647
Generalized maculopapular rash	18.8% Disc. AE	1500 mg 1 times / day multiple, oral Recommended Dose: 1500 mg, 1 times / day Route: oral Route: multiple Dose: 1500 mg, 1 times / day Co-administed with:: ofloxacin, p.o(800 mg/day; 6 months) Sources: https://pubmed.ncbi.nlm.nih.gov/8139647	healthy n = 16 Health Status: healthy Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8139647
Insomnia	18.8% Disc. AE	1500 mg 1 times / day multiple, oral Recommended Dose: 1500 mg, 1 times / day Route: oral Route: multiple Dose: 1500 mg, 1 times / day Co-administed with:: ofloxacin, p.o(800 mg/day; 6 months) Sources: https://pubmed.ncbi.nlm.nih.gov/8139647	healthy n = 16 Health Status: healthy Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8139647
Fatigue	25% Disc. AE	1500 mg 1 times / day multiple, oral Recommended Dose: 1500 mg, 1 times / day Route: oral Route: multiple Dose: 1500 mg, 1 times / day Co-administed with:: ofloxacin, p.o(800 mg/day; 6 months) Sources: https://pubmed.ncbi.nlm.nih.gov/8139647	healthy n = 16 Health Status: healthy Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8139647
Pruritus	25% Disc. AE	1500 mg 1 times / day multiple, oral Recommended Dose: 1500 mg, 1 times / day Route: oral Route: multiple Dose: 1500 mg, 1 times / day Co-administed with:: ofloxacin, p.o(800 mg/day; 6 months) Sources: https://pubmed.ncbi.nlm.nih.gov/8139647	healthy n = 16 Health Status: healthy Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8139647
Distress gastrointestinal	37.5% Disc. AE	1500 mg 1 times / day multiple, oral Recommended Dose: 1500 mg, 1 times / day Route: oral Route: multiple Dose: 1500 mg, 1 times / day Co-administed with:: ofloxacin, p.o(800 mg/day; 6 months) Sources: https://pubmed.ncbi.nlm.nih.gov/8139647	healthy n = 16 Health Status: healthy Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8139647
Arthralgia	43.75% Disc. AE	1500 mg 1 times / day multiple, oral Recommended Dose: 1500 mg, 1 times / day Route: oral Route: multiple Dose: 1500 mg, 1 times / day Co-administed with:: ofloxacin, p.o(800 mg/day; 6 months) Sources: https://pubmed.ncbi.nlm.nih.gov/8139647	healthy n = 16 Health Status: healthy Population Size: 16 Sources: https://pubmed.ncbi.nlm.nih.gov/8139647
Hepatotoxicity	5.8% Disc. AE	20 mg/kg 1 times / day multiple, oral Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg, 1 times / day Co-administed with:: rifampin, p.o(600 mg/d; 2 months) Sources: https://pubmed.ncbi.nlm.nih.gov/12379063 Page: p.643	unhealthy n = 207 Health Status: unhealthy Condition: Tuberculosis Sex: M+F Population Size: 207 Sources: https://pubmed.ncbi.nlm.nih.gov/12379063 Page: p.643
Hepatotoxicity	Disc. AE	30 mg/kg 1 times / day multiple, oral (max) Recommended Dose: 30 mg/kg, 1 times / day Route: oral Route: multiple Dose: 30 mg/kg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=257bd8cf-74d7-45db-bf25-354a8d26634e&type=display#LINK_5b1b9b20-2ad0-4c1c-b6cb-e086db370aff	unhealthy Health Status: unhealthy Condition: Tuberculosis Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=257bd8cf-74d7-45db-bf25-354a8d26634e&type=display#LINK_5b1b9b20-2ad0-4c1c-b6cb-e086db370aff

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP3A 214 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP2E1 882

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/early/2017/06/26/dmd.117.076034	no
CYP2B6 1001	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/early/2017/06/26/dmd.117.076034	no
CYP2C19 1553	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/early/2017/06/26/dmd.117.076034	no
CYP2C8 965	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/early/2017/06/26/dmd.117.076034	no
CYP2C9 1819	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/early/2017/06/26/dmd.117.076034	no
CYP2D6 1891	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/early/2017/06/26/dmd.117.076034	no
CYP2E1 970	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/early/2017/06/26/dmd.117.076034	no
CYP3A 298	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/early/2017/06/26/dmd.117.076034	no

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY427375	https://www.001chemical.com/chem/4238-71-5
001 Chemical	NO13379	https://www.001chemical.com/chem/98-96-4
3B Scientific (Wuhan) Corp	3B1-00092	http://www.3bsc.com/index/pro_info.php?id=20304
AA Blocks	AA003TZ0	https://www.aablocks.com/goods/Goods/detail?id=AA003TZ0
AK Scientific, Inc. (AKSCI)	265049	http://www.aksci.com/item_detail.php?cat=265049
AK Scientific, Inc. (AKSCI)	J10111	http://www.aksci.com/item_detail.php?cat=J10111
Aaron Chemicals	AR003UQS	http://www.aaronchem.com/98-96-4
AbMole Bioscience	M3299	http://www.abmole.com/products/pyrazinamide.html
Acadechem	ACDS-028210	http://www.acadechemical.com/product/102909
Accela ChemBio Inc	SY013550	http://www.accelachem.com/cn/search.html?keyword=SY013550&attname=GoodsCode
Achemica	ACMC-20aive	http://www.achemica.com/prodinfo/?id=132042
Achemo Scientific Limited	AC-76823	http://www.achemo.com/search/?Keyword= 98-96-4
Achemtek	0104-015515	http://www.achemtek.com/98-96-4
Acorn PharmaTech	ACN-038145	http://www.acornpharmatech.com/
Acros Organics	AC157640100	https://www.fishersci.com/shop/products/pyrazinamide-99-acros-organics/AC157640100
Acros Organics	AC157640250	https://www.fishersci.com/shop/products/pyrazinamide-99-acros-organics/AC157640250
Acros Organics	AC157641000	https://www.fishersci.com/shop/products/pyrazinamide-99-acros-organics/AC157641000
Alfa Chemistry	AP98964	https://reagents.alfa-chemistry.com/product/pyrazinamide-cas-98-96-4-19142.html
Alichem	99001189	http://www.alichem.com/en/products/98-96-4.html
Alsachim	2529	http://www.alsachim.com/product-C3602-glo.bal-view.html
Ambinter	Amb22166847	http://www.ambinter.com/reference/22166847
Angene	AGN-PC-07Q1HT	http://www.angenechemical.com/productshow/AGN-PC-07Q1HT.html
Anward	ANW-75384	http://www.anward.com/pro_result/61835
ApexBio Technology	B2122	http://www.apexbt.com/pyrazinamide.html
Ark Pharm	AK-94813	http://www.arkpharminc.com/products/98-96-4.html
Aurora Fine Chemicals LLC	A00.157.180	http://online.aurorafinechemicals.com/info?ID=A00.157.180
Aurora Fine Chemicals LLC	K01.795.399	http://online.aurorafinechemicals.com/info?ID=K01.795.399
Aurum Pharmatech LLC	M-7421	http://www.Aurumpharmatech.com/Product/ProductDetails/M_7421
BLD Pharm	BD17175	http://www.bldpharm.com/products/98-96-4.html
BOC Sciences	1246817-81-1	https://isotope.bocsci.com/product/pyrazine-d3-carboxamide-15n-cas-1246817-81-1-345056.html
BioChemPartner	BCP30257	http://www.biochempartner.com/98-96-4-BCP30257
BioCrick	BCC4932	http://www.biocrick.com/Pyrazinamide-BCC4932.html
BioSynth	W-100059	https://www.biosynth.com/en/products/chemical-intermediates/basic-intermediates/products/W-100059.html
CSNpharm	CSN12465	https://www.csnpharm.com/products/pyrazinamide.html
Chem Scene	CS-2260	http://www.chemscene.com/98-96-4.html
ChemMol	44010831	http://www.chemmol.com/chemmol/44010831.html
Chemenu	CM110203	http://www.chemenu.com/products/CM110203
Chemspace	CSSB00000162229	https://chem-space.com/CSSB00000162229
Clearsynth	CS-O-00733	https://www.clearsynth.com/en/CSO00733.html
DC Chemicals	DCAPI1405	http://www.dcchemicals.com//product_show-Pyrazinamide_Pyrazinoic_acid_amide_.html
Debye Scientific	DB-002866	http://www.debyesci.com/DB-002866.html
Enamine	Z33546644	https://www.enaminestore.com/catalog/Z33546644
Finetech	FT-0659757	http://www.finetechnology-ind.com/prod/detail/pub/98-96-4.html
Glentham Life Sciences	GA1140	http://www.glentham.com/products/product/GA1140/
Hairui	HR134410	http://www.hairuichem.com/en/product/98-96-4.html
Huateng Pharma	F80006455	http://en.huatengsci.com/product/Pyrazinamide.html
LGC Standards	DRE-C16608000	https://www.lgcstandards.com/US/en/p/DRE-C16608000
LGC Standards	LGCFOR0385.00	https://www.lgcstandards.com/US/en/p/LGCFOR0385.00
LGC Standards	MM0385.00	https://www.lgcstandards.com/US/en/p/MM0385.00
Lab Network	LN00185010	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00185010
Matrix Scientific	85417	https://www.matrixscientific.com/085417.html
MedChem Express	HY-B0271	https://www.medchemexpress.com/pyrazinamide.html
Molcore	MC427375	https://www.molcore.com/product/4238-71-5
Molcore	CS13379	https://www.molcore.com/product/98-96-4
MuseChem	A000469	https://www.musechem.com/product/A000469.html
Oakwood	68696	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=58015&ExtHyperLink=1
Otava	1375193	https://search.otavachemicals.com/#!/search?query=1375193&type=code&base=dbb
Sigma-Aldrich	40751_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/40751?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP906_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp906?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	P4050000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/p4050000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	P7136_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/p7136?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1585006_USP	https://www.sigmaaldrich.com/catalog/product/usp/1585006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S012553	http://www.sinfoobiotech.com/product/1015951
Smolecule	S540690	http://www.smolecule.com/products/s540690
Smolecule	S793272	https://www.smolecule.com/products/s793272
TCI (Tokyo Chemical Industry)	P0633	http://www.tcichemicals.com/eshop/en/us/commodity/P0633/index.html
THE BioTek	bt-280889	https://www.thebiotek.com/product/inhibitors/bt-280889
Vitas-M Laboratory	BBL010592	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL010592&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
VladaChem	VL120458	https://www.vladachem.com/product.php?products=98-96-4
VladaChem	VL276551-100G	https://www.vladachem.com/product.php?products=98-96-4
abcr GmbH	AB251460	http://www.abcr.com/shop/en/AB251460
iChemical	EBD430	http://www.ichemical.com/products/98-96-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-6846697749	https://mcule.com/MCULE-6846697749/

PubMed

Title	Date	PubMed
Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis.	2001	11737875
The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.	2001	11686881
[Effectiveness of chemotherapy of intrathoracic tuberculosis in children: late follow-up data].	2001	11588952
Pancreatic mass caused by Mycobacterium tuberculosis with reduced drug sensitivity.	2001 Apr	11545552
Pulmonary tuberculosis in Kumasi, Ghana: presentation, drug resistance, molecular epidemiology and outcome of treatment.	2001 Apr-Jun	11768026
[Functional role of the red nucleus in the cerebral cortex-cerebellum-spinal cord communication system].	2001 Apr-Jun	11548591
Renal handling of uric acid assessed by means of pharmacological tests in obese women.	2001 Aug	11716287
Rifampicin allergy confirmed by an intradermal test, but with a negative patch test.	2001 Aug	11553123
Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.	2001 Aug 31	11787580
Can serial qualitative polymerase chain reaction monitoring predict outcome of pulmonary tuberculosis treatment?	2001 Dec	11844121
[Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].	2001 Dec	11806128
Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.	2001 Dec	11804071
Pyrazinamide use as a method of estimating under-reporting of tuberculosis.	2001 Dec	11769775
Side effects of antituberculosis treatment.	2001 Dec	11758512
Postantibiotic effects of antituberculosis agents alone and in combination.	2001 Dec	11709357
New mutations in pncA of in vitro selected pyrazinamide-resistant strains of Mycobacterium tuberculosis.	2001 Fall	11759083
Pattern of some haematological indices in newly diagnosed pulmonary tuberculosis cases in Iwo, Nigeria: diagnostic and therapeutic implications.	2001 Jan-Mar	11705048
Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization.	2001 Jul	11679013
[Multiple intracranial tuberculomas in infancy].	2001 Jul 1-15	11562860
Tuberculosis and HIV infection: epidemiology, immunology, and treatment.	2001 Jul-Aug	11590540
Antimycobacterial plant terpenoids.	2001 Nov	11731906
Pyrazinamide induced photoallergy.	2001 Nov	11716347
Tuberculous meningitis: is a 6-month treatment regimen sufficient?	2001 Nov	11716339
Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis.	2001 Nov	11684559
Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR.	2001 Nov	11600372
Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii.	2001 Nov 27	11714269
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.	2001 Nov 9	11684933
[Orchiectomy for tuberculous epididymitis: a report of two cases with intractable to antituberculosis treatment].	2001 Oct	11712389
Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea.	2001 Oct	11641519
Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa.	2001 Oct	11605890
Treatment of tuberculosis in Haiti.	2001 Oct	11574298
Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers.	2001 Oct 1	11673194
Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.	2001 Oct 2	11599338
[Vesical uric acid lithiasis in a child with renal hypouricemia].	2001 Sep	11676906
Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report.	2001 Sep	11595068
Intramedullary tuberculoma of the conus medullaris: case report and review of the literature.	2001 Sep	11571663
Modulating effect of Liv.100, an ayurvedic formulation on antituberculosis drug-induced alterations in rat liver microsomes.	2001 Sep	11536379
Tuberculosis: guidelines changed for latent TB treatment.	2001 Sep 21	11668976
From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.	2001 Sep 26	11596606
US guidelines for treatment of latent tuberculosis revised.	2001 Sep 8	11564495
Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.	2002 Feb	11840073
Tuberculosis presenting as immune thrombocytopenic purpura.	2002 Feb	11836186
Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.	2002 Jan	11800471
Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.	2002 Jan	11800467
High rates of tuberculosis in end-stage renal failure: the impact of international migration.	2002 Jan	11749753
Surveillance for antimicrobial resistance in Croatia.	2002 Jan	11749742
Rapidly progressive glomerulonephritis due to rifampicin therapy.	2002 Jan	11744817
Liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin from pharmaceutical preparations and blood.	2002 Jan 25	11829003
Therapeutic isoniazid monitoring using a simple high-performance liquid chromatographic method with ultraviolet detection.	2002 Jan 5	11820293
Tuberculoma of the conus medullaris: case report.	2002 Mar	11841737

Patents

Sample Use Guides

In Vivo Use Guide

15 to 30 mg/kg once daily

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

PYRAZINAMIDE

Official Name

English

PYRAZINAMIDE [USP-RS]

Common Name

English

D-50

Code

English

PYRAZIDE

Common Name

English

PYRAZINAMIDE [MART.]

Common Name

English

PYRAZINAMIDE COMPONENT OF RIFATER

Common Name

English

PYRAZINAMIDE [HSDB]

Common Name

English

PYRAZINAMIDE [USP MONOGRAPH]

Common Name

English

PYRAFAT

Common Name

English

PYRAMIZADE

Common Name

English

PIRAZINAMID

Common Name

English

PYRAZINAMIDE [MI]

Common Name

English

RIFATER COMPONENT PYRAZINAMIDE

Common Name

English

Pyrazinecarboxamide

Systematic Name

English

PYRAZINAMIDE [JAN]

Common Name

English

ZINAMIDE

Common Name

English

ALDINAMID

Common Name

English

NOVAMID

Common Name

English

PYRAZINAMIDE [VANDF]

Common Name

English

ALDINAMIDE

Common Name

English

PYRAZINAMIDE [USP IMPURITY]

Common Name

English

FARMIZINA

Common Name

English

NSC-14911

Code

English

pyrazinamide [INN]

Common Name

English

PYRAZINAMIDE [ORANGE BOOK]

Common Name

English

UNIPYRANAMIDE

Common Name

English

PIRAZIMIDA

Common Name

English

PYRAZINAMIDUM [WHO-IP LATIN]

Common Name

English

PYRAZINAMIDE [EP MONOGRAPH]

Common Name

English

MK-56

Code

English

PYRAZINE CARBOXYLAMIDE

Common Name

English

.ALPHA.-PYRAZINAMIDE

Common Name

English

ISOPAS

Common Name

English

PYRAZINAMIDE [WHO-IP]

Common Name

English

ROZIDE

Common Name

English

TEBRAZID

Common Name

English

Pyrazinamide [WHO-DD]

Common Name

English

EPRAZIN

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C280